By
Trending Posts
How Are NUS and UC San Diego Using…
Key Highlights: AI-Powered Personalization: Unlocking Sex-Specific Drug EfficacyThe collaboration between the National University of Singapore’s WisDM and UC…
Will XtalPi’s AI-Driven Acquisition of LCC Redraw the…
Key Highlights: AI Meets Chiral Chemistry in Strategic UK AcquisitionXtalPi Holdings Ltd. (HKEX: 2228), the AI-powered drug discovery…
Is DeepCure’s AI-Designed Oral STAT6 Inhibitor the Next…
Key Highlights: Oral Option for Dupilumab-Class PatientsDeepCure’s newly nominated candidate DC-15442 offers a breakthrough alternative to injectable biologics…
How Novo Nordisk and Deep Apple’s $812M AI-Powered…
Key Highlights: A Bold Break from Incretin DependencyNovo Nordisk’s new alliance with Deep Apple Therapeutics marks a critical…
How Will HEALWELL AI and Orion Health Transform…
Key Highlights: Strategic Expansion into US Healthcare MarketHEALWELL AI Inc., following its acquisition of Orion Health, announces a…
Can GenepoweRx and MGI Tech’s AI-Driven Genomic Partnership…
Key Highlights: Strategic Alliance to Revolutionize Genomic MedicineIndian AI-driven startup GenepoweRx and China’s MGI Tech have joined forces…
Bexorg and Biohaven: Can Their AI-Driven Whole-Brain Discovery…
Key Highlights: Strategic Collaboration to Transform CNS TherapeuticsBexorg, a techbio innovator focused on decoding the human brain, has…
Tevogen AI & Microsoft: Will Their AI &…
Key Highlights HQ Expansion to Power AI, Generics & Biosimilar VisionTevogen Bio Holdings Inc. (Nasdaq: TVGN) has more…
AlphaMeld AI and VedTechBio: Can Their AI Alliance…
Key Highlights Strategic Alliance to Bridge AI Discovery and Translational ExecutionAlphaMeld Corporation, a global leader in AI-native drug…
Trending Posts
Latest Stories
Is Lilly’s “TuneLab” the Breakthrough AI Collaboration Model Biotech Startups Have Been Waiting For?
Key Highlights A bold move: Lilly democratizes AI for biotechEli Lilly has launched TuneLab, a…
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in Phase 3 Trials?
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing…
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and Sustained Efficacy in Over 2,600 Patients?
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results…
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN…
Gallery
